Skip Navigation

JNCI Journal of the National Cancer Institute 2005 97(10):778-779; doi:10.1093/jnci/dji135
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (5)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Wang-Gohrke, S.
Right arrow Articles by Chang-Claude, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wang-Gohrke, S.
Right arrow Articles by Chang-Claude, J.
Related Collections
Right arrowRelated Correspondence
Right arrowResponse to this Correspondence
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 Oxford University Press

CORRESPONDENCE

Re: Integrin {beta}3 Leu33Pro Homozygosity and Risk of Cancer

Shan Wang-Gohrke, Jenny Chang-Claude

Affiliations of authors: Molecular Biology Laboratory, Department of Obstetrics & Gynecology, University of Ulm, Prittwitzstrasse 43, D-89075 Ulm, Germany (SWG); Division of Clinical Epidemiology, Deutsches Krebsforschungszentrum, Postfach 101949, 69009 Heidelberg, Germany (JCC)

Correspondence to: For correspondence regarding molecular biology: Shan Wang-Gohrke, MD, Department of Obstetrics and Gynecology, University of Ulm, Prittwitzstrasse 43, D-89075 Ulm, Germany (e-mail: shan.wang@medizin.uni-ulm.de); for correspondence regarding epidemiology: Jenny Chang-Claude, PhD, Division of Clinical Epidemiology, Deutsches Krebsforschungszentrum, Postfach 101949, 69009 Heidelberg, Germany (e-mail: J.Chang-Claude@dkfz.de).

The first 10% of the full text of this article appears below.

Integrins are transmembrane {alpha}{beta} heterodimers that function as key surface adhesion and cell signaling receptors influencing cell proliferation and migration. Overexpression of integrin {beta}3 is associated with progression to invasive tumors, whereas inhibition of {beta}3 integrin expression and/or function is associated with a reduction in tumor growth and metastasis. Specific {beta}3 integrin inhibitors are being developed as cancer drugs, some of which are already in clinical trials.

A functional polymorphism . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related Correspondence

Re: Integrin {beta}3 Leu33Pro Homozygosity and Risk of Cancer
Qianren Jin, Kari Hemminki, Ewa Grzybowska, Rüdiger Klaes, Magnus Söderberg, and Asta Försti
J Natl Cancer Inst 2004 96: 234-235. [Extract] [Full Text] [PDF]

Response to this Correspondence

RESPONSE: Re: Integrin {beta}3 Leu33Pro Homozygosity and Risk of Cancer
Stig Egil Bojesen, Anne Tybjærg-Hansen, and Børge Grønne Nordestgaard
J Natl Cancer Inst 2005 97: 779-780. [Extract] [Full Text] [PDF]



This article has been cited by other articles:


Home page
 CarcinogenesisHome page
A. Brendle, H. Lei, A. Brandt, R. Johansson, K. Enquist, R. Henriksson, K. Hemminki, P. Lenner, and A. Forsti
Polymorphisms in predicted microRNA-binding sites in integrin genes and breast cancer: ITGB4 as prognostic marker
Carcinogenesis, July 1, 2008; 29(7): 1394 - 1399.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
S E Bojesen, S K Kjaer, E V S Hogdall, B L Thomsen, C K Hogdall, J Blaakaer, A Tybjaerg-Hansen, and B G Nordestgaard
Increased risk of ovarian cancer in integrin {beta}3 Leu33Pro homozygotes
Endocr. Relat. Cancer, December 1, 2005; 12(4): 945 - 952.
[Abstract] [Full Text] [PDF]